| Home | Events | Refractive Surgery | Product Showroom | About NIDEK | News | Try Your Eyes | Contact Us | Site Map |

Product Showroom

Y2K Compliance Info


Excimer Laser

Multi-wavelength Laser

Argon Laser

Yag Laser

Green Yag Laser

Diode Laser

Combination Lasers

Laser Slit Lamp









Important Note: The Nidek Excimer Laser EC-5000 is not approved for sale in several countries yet. For more information please contact Nidek.
(Caution for the United States only.)
CAUTION - Investigational Device. For PARK, LASIK, PTK, or any use other than PRK, is limited by United States Law to investigational use.

Nidek's Model EC-5000 Excimer Laser is designed to reshape the cornea for PRK, PARK (consecutive correction of myopia and astigmatism) and PTK.


Smooth Ablation Surface that is free from the ridges or grooves that are commonly generated by first generation excimer.

Dynamic Rotating and Overlapping Delivery System designed to perform refractive and therapeutic treatments over a large ablation area.

Result in Less Corneal Temperature Rise than first generation excimer.

An Easy and Effective Alignment System provided by a 3D motorized joystick along with improved illumination and aiming beams.

Fully Computerized Performance. Laser delivery parameters are automatically calculated by entering the basic data. During that ablation procedure, the computer monitors system parameters continuously.

Low Running Cost. The EC-5000 offers a large number of treatments per fill of gas.

Risks and Benefits:

The United States Food and Drug Administration (FDA) has approved the Nidek EC-5000 Excimer Laser System for use in the United States to perform photorefractive keratectomy (PRK) for the reduction or elimination of myopia in the low, moderate, or high ranges (-0.75 to -13.00 D), spherical equivalent at the spectacle plane, uncomplicated by refractive astigmatism (i.e. 0.75 D or less in any meridian).

Alternatives to PRK: Eyeglasses, contact lenses, LASIK, radial keratotomy or automated lamellare keratoplasty. In studies of 587 eyes (consistent cohort) after final treatment with refractive data at 6 months, 91.3% were corrected to 20/40 or better and 60.6% were corrected at 20/20 or better without spectacles or contact lenses.

U.S. Clinical Trial Adverse Events: The percentage of individuals with 20/20 or better per-op had best corrected spectacle visual acuity worse than 20/25 in the following proportions: 4.0% (-6.00 to -9.00 D) and 4.8% (> -10.00 D).

U.S. Clinical Trial Complications: An increase in fluctuation of vision (34.1% pre-op vs. 48.1% post-op); glare (26.9% pre-op vs. 34.4% post-op); and difficulty in night driving (23.5% pre-op vs. 48% post-op).

Check also our EAS-1000 Anterior Eye Segment Analysis System for evaluation of corneal haze in post PRK patients.

Doctors only!: Our newsletter Excimer Express brings you the latest news and topics on Nidek's EC-5000.

For more information on product and local distributor
please fill out our Registration Form or e-mail us.


Top of this page


© Copyright 1999 Nidek e-mail to Nidek